Viking Therapeutics
VKTX
144 hedge funds and large institutions have $280M invested in Viking Therapeutics in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 46 increasing their positions, 42 reducing their positions, and 25 closing their positions.
122% more call options, than puts
Call options by funds: $17.3M | Put options by funds: $7.82M
10% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6.22% less ownership
Funds ownership: 62.59% → 56.37% (-6.2%)
8% less funds holding
Funds holding: 156 → 144 (-12)
25% less capital invested
Capital invested by funds: $374M → $280M (-$94.2M)
44% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$9.51M |
| 2 |
AG
Artal Group
Luxembourg
|
+$1.86M |
| 3 |
SG Americas Securities
New York
|
+$1.67M |
| 4 |
Millennium Management
New York
|
+$1.26M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$1.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$22.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.17M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$4.02M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$3.95M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.32M |
VKTX Hedge Fund Activity: Q3 2019 in Review
144 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2019, worth a combined $280M — down 25% from $374M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of VKTX and 14 opened new positions — a net loss of 11 holders — while 42 trimmed existing stakes and 46 added.
The largest buyer was ArrowMark Colorado Holdings, adding an estimated $9.51M. The largest seller was State Street, cutting an estimated $22.8M.
- 144 institutional investors held Viking Therapeutics (VKTX) as of Q3 2019, down from 156 in Q2 2019.
- Funds reported $280M of Viking Therapeutics stock for Q3 2019, down 25% quarter-over-quarter.
- 14 funds opened new Viking Therapeutics positions in Q3 2019 and 25 closed out, a net change of -11 holders.
- The largest Viking Therapeutics buyer in Q3 2019 was ArrowMark Colorado Holdings, an estimated $9.51M added.
- The largest Viking Therapeutics seller in Q3 2019 was State Street, an estimated $22.8M sold.
Based on aggregated 13F filings for Q3 2019.